Generic Name and Formulations:
Tetrahydrozoline HCl 0.1%; nasal soln; contains benzalkonium chloride.
Indications for TYZINE:
Adults and Children:
<6yrs: see Contraindications. ≥6yrs: 2–4 drops in each nostril as needed; max: every 3hrs.
Children <6yrs. Concomitant MAO inhibitors.
Do not exceed recommended doses. Cardiovascular disease. Hyperthyroidism. Diabetes. Discontinue if adverse reactions occur. Children. Pregnancy (Cat.C). Nursing mothers.
Hypertensive crisis with MAOIs.
Local effects (eg, burning, stinging, sneezing, dryness of the mucosa), headaches, drowsiness, weakness, tremors, lightheadedness, insomnia, palpitations, rebound congestion.
Soln—15mL (w. dropper)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML